India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
PMDA is regarded among the most stringent regulatory bodies globally
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
